What is Taliglucerase Alfa?
Taliglucerase is an alternative to an enzyme for people suffering from Type I Gaucher disease as well as children aged 4 or more years. Gaucher's disease is an inherited illness that causes the body to lack the enzyme required to break down certain fats (lipids). Lipids build up within the body, leading to symptoms such as bleeding or bruising, weakness, anaemia, bone or joint discomfort, an enlarged liver, the spleen, or weak bones that are prone to fracture.
Taliglucerase could improve the condition of the spleen, liver bones, and blood cells of people suffering from Type I Gaucher's disease. It is important to note that taliglucerase does not provide a cure for this condition. Taliglucerase can be used for other purposes not covered in this medication guide.
Side effects of Taliglucerase Alfa
Contact a medical professional immediately. If you are experiencing symptoms that are warning signs of an allergic response, such as difficulty breathing, hives, or swelling of your lips, face, and tongue,
Certain people who have received a taliglucerase alfa injection may have an allergic reaction after the medication was injected or as long as 3 hours after. Inform your healthcare providers immediately when you suffer from:
The feeling that you could pass out;
Chest tightness; coughing;
The appearance of swelling on your face;
Cough, throat irritation
Flushing (warmth, redness, or a tingly sensation);
Skin, itching, or the appearance of redness.
Common adverse consequences of taliglucerase alfa could be:
Itching, rash, or tingling sensation;
Fatigue or dizziness;
Nausea, stomach pain, vomiting, or
Joint pain, lower back discomfort, back pain, arm pain, or leg pain
This isn't a complete list of possible side effects, and others could happen. Consult your physician to seek medical advice on the effects. You can report any side effects to the FDA at 1-800-FDA-1088.
Certain people who have received a taliglucerase alfa injection have experienced reactions when the medication was administered or as long as 3 hours after. Contact your doctor immediately in the event of an unexpected headache, dizziness, tingling in your chest, nausea, wheezing, or a rash on your skin that is red.
Before you take this drug
Inform your doctor if you are expecting. It isn't known if Taliglucerase Alfa can cause harm to a newborn baby. But if you have untreated or controlled Type I Gaucher disease during pregnancy, it can result in new or more severe symptoms for the mother or complications for the baby, such as bleeding problems or growth. The benefits of treating your condition can outweigh any risk for the baby.
It might not be safe to breastfeed while taking this medication. Talk to your doctor about any potential risks.
What exactly do you know taliglucerase alfa is used for?
Taliglucerase alfa is administered as an injection into the vein. Your healthcare professional will give the injection. You might also be prescribed additional medications to avoid any allergic reactions. Use these medications as long as your physician prescribes them.
You could be prescribed different medications to help prevent certain negative side effects from Taliglucerase alfa. Taliglucerase alfa is generally administered every two weeks. Follow the doctor's instructions for dosage extremely carefully. Your doctor might alter the dosage to ensure you are getting the best results. Taliglucerase dosages for alfa are dependent on weight (especially for adolescents and children). Your dose needs may change if you gain or lose weight.
Details on dosage:
Usual Adult Dose for Gaucher Disease:
Initial dose: 60 units/kg IV once every other week.
Conversion to imiglucerase:
For patients who are on an imiglucerase dose that is stable Start at the identical units/kg IV dose every two weeks.
Adjustments to dosages should be determined by the patient's therapeutic goals.
Administration as an IV infusion between 60 and 120 minutes at least once a week. For adult patients, a starting dose of 1.2 millilitres per minute is recommended.
After tolerance to infusion has been established, the rate of infusion can be increased, but it must not exceed the maximum suggested for infusion of 2.2 mg/min; infusions should be given within a maximum of 60 minutes.
Use: To provide long-term, ongoing enzyme replacement therapy (ERT) for patients with a confirmed diagnosis of Gaucher disease type 1.
Usual Paediatric Dose for Gaucher Disease:
Ages 4 and over:
Naive treatment: Initial dose: 60 units/kg IV every second week
Conversion to imiglucerase
For patients who are on an imiglucerase dose that is stable, begin with similar doses per kg every two weeks.
The dosage adjustments must be determined by the therapeutic goals of each patient.
Administration as an IV infusion between 60 and 120 minutes each week. In adult patients, a starting dose of 1.2 millilitres per minute is recommended.
Once tolerance to infusion has been established, the rate of infusion can be increased; however, it is not required to exceed the maximum suggested dose of 2.2 millilitres per minute; the infusion is recommended to be administered in a minimum of 60 minutes.
Use: To treat patients who have an established diagnosis of Type 1 Gaucher disease.
What happens if I miss a dose?
Contact your doctor for advice. If you do not make an appointment to receive your taliglucerase injection,
What happens when I take too much?
For medical emergencies, seek emergency medical attention or contact the Poison Help line at 1-800-222-1222.
What should be avoided?
Follow the instructions of your physician regarding any limitations on foods, drinks, or activities.
Interaction with other drugs
Other medications may interact with taliglucerase alfa, which includes prescription and non-prescription medicines, vitamins, and herbal products. Discuss with your doctor the medicines you are currently taking and any medications you begin or stop taking.